By Sean Zheng Key messages Heart failure with preserved ejection fraction (HFPEF) is a common cause of hospitalisation, impaired quality of life, restricted functional capacity,…
View More Heart failure with preserved ejection fraction
Tag: Heart Failure and Cardiomyopathies
Sodium-glucose co-transporter 2 inhibitors – new frontier in the treatment of heart failure
By Syed Ghias Take Home Messages Sodium-glucose co-transporter-2 (SGLT-2) inhibitors are a novel class of oral hypoglycaemic medications which have been shown to be effective…
View More Sodium-glucose co-transporter 2 inhibitors – new frontier in the treatment of heart failure
Artificial Intelligence, precision phenotyping and risk prediction in cardiomyopathy
By Ahmed El-Medany Presented by Prof O’Regan, MRC Investigator and Consultant Radiologist, Imperial College London The Digital Innovation in Cardiology session at BCS 2021 was…
View More Artificial Intelligence, precision phenotyping and risk prediction in cardiomyopathy
Depression associated with increased risk of heart failure events and sudden cardiac death in hypertrophic cardiomyopathy
Hu et al sought to investigate the impact of depression on clinical outcomes in individuals with hypertrophic cardiomyopathy (HCM)
View More Depression associated with increased risk of heart failure events and sudden cardiac death in hypertrophic cardiomyopathyBeyond Diabetes: The Impact of Empagliflozin in Heart Failure with Reduced Ejection Fraction
(Taken from Expert Analysis- ACC) This secondary analysis from the EMPEROR-Reduced trial shows that use of empagliflozin reduces the risk of CV death or HF…
View More Beyond Diabetes: The Impact of Empagliflozin in Heart Failure with Reduced Ejection Fraction